These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 35602817)
1. Real-World Evidence of Efficacy and Safety of Levonadifloxacin (Oral and IV) in the Management of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Findings of a Retrospective, Multi-Center Study. Mehta KD; Sharma JB; Anand A; Reddy N PK; Kadam P; Debnath K; Bhapkar S; Thampi BM Cureus; 2022 Apr; 14(4):e24299. PubMed ID: 35602817 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study. Bhatia A; Mastim M; Shah M; Gutte R; Joshi P; Kumbhar D; Periasamy H; Palwe SR; Chavan R; Bhagwat S; Patel M; Llorens L; Friedland HD J Assoc Physicians India; 2020 Aug; 68(8):30-36. PubMed ID: 32738837 [TBL] [Abstract][Full Text] [Related]
3. Prescription-Event Monitoring Study on Safety and Efficacy of Levonadifloxacin (Oral and I.V.) in Management of Bacterial Infections: Findings of Real-World Observational Study. Mehta Y; Sutar AR; Zirpe K; Kothari JN; Alapati C; Pathak M; Nagvekar VC; Mehta KD; Debnath K Int J Appl Basic Med Res; 2022; 12(1):30-36. PubMed ID: 35265478 [TBL] [Abstract][Full Text] [Related]
4. Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence. Bhagwat SS; Nandanwar M; Kansagara A; Patel A; Takalkar S; Chavan R; Periasamy H; Yeole R; Deshpande PK; Bhavsar S; Bhatia A; Ahdal J; Jain R; Patel M Drug Des Devel Ther; 2019; 13():4351-4365. PubMed ID: 31920285 [TBL] [Abstract][Full Text] [Related]
5. Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin. Mehta Y; Mishra KC; Paliwal Y; Rangappa P; Sinha S; Bhapkar S Crit Care Res Pract; 2022; 2022():2668199. PubMed ID: 36785544 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18. Appalaraju B; Baveja S; Baliga S; Shenoy S; Bhardwaj R; Kongre V; Dattatraya GS; Dhole T; Verma B; Mukherjee DN; Gupta S; Shanmugam P; Iravane J; Mishra SR; Barman P; Chopra S; Hariharan M; Surpam R; Pratap R; Joshi P; Khande H; Mane A; Jain R; Bhagwat S J Antimicrob Chemother; 2020 Mar; 75(3):600-608. PubMed ID: 31840170 [TBL] [Abstract][Full Text] [Related]
7. Assessment of antibacterial activity of levonadifloxacin against contemporary gram-positive clinical isolates collected from various Indian hospitals using disk-diffusion assay. Baliga S; Mamtora DK; Gupta V; Shanmugam P; Biswas S; Mukherjee DN; Shenoy S Indian J Med Microbiol; 2020; 38(3 & 4):307-312. PubMed ID: 33154240 [TBL] [Abstract][Full Text] [Related]
8. India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care. Veeraraghavan B; Bakthavatchalam YD; Manesh A; Lal B; Swaminathan S; Ansari A; Subbareddy K; Rangappa P; Choudhuri AH; Nagvekar V; Mehta Y; Appalaraju B; Baveja S; Baliga S; Shenoy S; Bhardwaj R; Kongre V; Dattatraya GS; Verma B; Mukherjee DN; Gupta S; Shanmugam P; Iravane J; Mishra SR; Barman P; Chopra S; Hariharan M; Surpam R; Pratap R; Turbadkar D; Taklikar S; Indian J Med Microbiol; 2023; 41():71-80. PubMed ID: 36509611 [TBL] [Abstract][Full Text] [Related]
9. Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital. Bakthavatchalam YD; Shankar A; Muniyasamy R; Peter JV; Marcus Z; Triplicane Dwarakanathan H; Gunasekaran K; Iyadurai R; Veeraraghavan B J Antimicrob Chemother; 2020 Aug; 75(8):2156-2159. PubMed ID: 32361727 [TBL] [Abstract][Full Text] [Related]
10. In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital. Mamtora D; Saseedharan S; Rampal R; Joshi P; Bhalekar P; Ahdal J; Jain R J Lab Physicians; 2020 Dec; 12(3):230-232. PubMed ID: 33268943 [No Abstract] [Full Text] [Related]
11. Levonadifloxacin arginine salt to treat acute bacterial skin and skin structure infection due to S. aureus including MRSA. Saxena D; Kaul G; Dasgupta A; Chopra S Drugs Today (Barc); 2020 Sep; 56(9):583-598. PubMed ID: 33025952 [TBL] [Abstract][Full Text] [Related]
12. A comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin-resistant Bakthavatchalam YD; Rao SV; Isaac B; Manesh A; Nambi S; Swaminathan S; Nagvekar V; Nangia V; John PV; Veeraraghavan B Indian J Med Microbiol; 2019; 37(4):478-487. PubMed ID: 32436868 [TBL] [Abstract][Full Text] [Related]
13. In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms. Tellis M; Joseph J; Khande H; Bhagwat S; Patel M J Med Microbiol; 2019 Aug; 68(8):1129-1136. PubMed ID: 31241446 [TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection. Bhawsar S; Kale R; Deshpande P; Yeole R; Bhagwat S; Patel M Bioorg Med Chem Lett; 2021 Dec; 54():128432. PubMed ID: 34757217 [TBL] [Abstract][Full Text] [Related]